Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study
A partir des données des registres danois des cancers portant sur 4 117 patientes atteintes d'un cancer épithélial de l'ovaire sur la période 2000-2012, cette étude évalue l'association entre des prescriptions de faibles doses d'aspirine après le diagnostic et la mortalité
Background: Increasing data suggest that aspirin use may improve cancer survival; however, the evidence is sparse for ovarian cancer. Methods: We examined the association between postdiagnosis use of low-dose aspirin and mortality in a nationwide cohort of women with epithelial ovarian cancer between 2000 and 2012. Information on filled prescriptions of low-dose aspirin, dates and causes of death, and potential confounding factors was obtained from nationwide Danish registries. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer-specific or other-cause mortality associated with low-dose aspirin use. Results: Among 4117 patients, postdiagnosis use of low-dose aspirin was associated with HRs of 1.02 (95% CI: 0.87–1.20) for ovarian cancer mortality and 1.06 (95% CI: 0.77–1.47) for other-cause mortality. Hazard ratios remained neutral according to patterns of low-dose aspirin use, including prediagnosis use or established mortality predictors. Conclusions: Low-dose aspirin use did not reduce mortality among ovarian cancer patients